#InsightNetwork | ATAI Life Sciences AG

Mental health in a time of COVID-19

Whether you’re on lockdown or just practicing social distancing, chances are you’re beginning to…

EntheogeniX Biosciences gets going

Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals…

Reflections on the progress of psychedelic medicine

Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience

ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

GABA Therapeutics commences phase I study of Etifoxine

ATAI’s Chief Scientific Officer addresses the future of psychiatric drug development at ISAD19

ATAI Life Sciences and Cyclica launch joint venture to revolutionize drug development for mental health disorders

Social Comparisons: Effects on Mental Health

(Originally published on ATAI.life on November 2, 2019)